Alector, Inc. (ALEC)
| Market Cap | 275.79M -2.3% |
| Revenue (ttm) | 13.86M -82.9% |
| Net Income | -117.85M |
| EPS | -1.09 |
| Shares Out | 111.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 915,025 |
| Open | 2.380 |
| Previous Close | 2.460 |
| Day's Range | 2.330 - 2.610 |
| 52-Week Range | 1.090 - 3.400 |
| Beta | 0.65 |
| Analysts | Hold |
| Price Target | 3.10 (+25.51%) |
| Earnings Date | Aug 6, 2026 |
About ALEC
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body... [Read more]
Financial Performance
In 2025, Alector's revenue was $21.05 million, a decrease of -79.07% compared to the previous year's $100.56 million. Losses were -$142.93 million, 20.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ALEC stock is "Hold." The 12-month stock price target is $3.1, which is an increase of 25.51% from the latest price.
News
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neuro...
Alector reports Q2 EPS (21c), consensus (23c)
Reports Q2 revenue $3.32M, consensus $1.71M. “We continue to make steady progress across our ABC-enabled preclinical and research pipeline,” said Arnon Rosenthal, Chief Executive Officer of Alector (A...
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program...
Alector Quarterly report: Q2 2026
Alector has published its Q2 2026 quarterly earnings report on August 6, 2026.
Alector Earnings release: Q2 2026
Alector released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Alector Slides: Corporate presentation
Alector has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.
Alector reports Q1 EPS (21c), consensus (28c)
Reports Q1 revenue $1.05M, consensus $11.03M. “Over the past seven years, we have built a highly differentiated blood-brain barrier platform with the versatility to deliver antibodies, enzymes, protei...
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody fo...
Alector Quarterly report: Q1 2026
Alector has published its Q1 2026 quarterly earnings report on May 7, 2026.
Alector Earnings release: Q1 2026
Alector released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Alector price target raised to $2 from 90c at Morgan Stanley
Morgan Stanley raised the firm’s price target on Alector (ALEC) to $2 from 90c and keeps an Underweight rating on the shares. AL101’s failure in the Phase 2 PROGRESS-AD trial…
Alector to discontinue PROGRESS-AD trial of nivisnebart
Alector (ALEC) confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart in individuals with early Alzheimer’s disease will be discontinued. The decision follows a pre-specified futility analysis co...
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including ...
Alector Proxy statement: Proxy filing
Alector filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Alector Proxy statement: Proxy filing
Alector filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Alector upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Pete Stavropoulos upgraded Alector (ALEC) to Overweight from Neutral. The Alector Brain Carrier platform positions Alector to become a major player in the neurodegenerative s...
Alector Slides: Corporate presentation
Alector has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
Alector files $400M mixed securities shelf
16:11 EDT Alector (ALEC) files $400M mixed securities shelf
Alector Registration statement: Registration Filing
Alector filed a registration statement on March 12, 2026, providing details about a securities offering with the SEC.
BTIG upgrades Alector to Buy on shift to novel therapeutics
BTIG analyst Thomas Shrader upgraded Alector (ALEC) to Buy from Neutral with a $6 price target The upgrade reflects the company’s shift in focus to the development of novel therapeutics…
Alector upgraded to Buy from Neutral at BTIG
BTIG upgraded Alector (ALEC) to Buy from Neutral with a $6 price target
Alector Transcript: TD Cowen 46th Annual Health Care Conference
The ABC platform enables efficient delivery of antibodies, enzymes, and siRNAs to the brain, showing strong preclinical efficacy and safety. Lead programs are advancing toward IND, with phase 1 trials planned to demonstrate rapid amyloid clearance in Alzheimer’s patients using subcutaneous dosing.
Alector reports Q4 EPS (34c), consensus (36c)
Reports Q4 revenue $6.2M, consensus $1.96M. “Alector’s (ALEC) strength lies in the combination of a highly differentiated blood-brain barrier platform and a team with deep experience executing complex...
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid anti...